Alexion Pharmaceuticals Inc. (ALXN)

125.36
0.21 0.17
NASDAQ : Health Technology
Prev Close 125.15
Open 125.39
Day Low/High 123.10 / 126.74
52 Wk Low/High 92.56 / 141.86
Volume 1.62M
Avg Volume 1.37M
Exchange NASDAQ
Shares Outstanding 224.24M
Market Cap 28.47B
EPS 0.30
P/E Ratio 13.48
Div & Yield N.A. (N.A)
A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

ULTOMIRIS® (ravulizumab) Receives Marketing Authorization From Japan's Ministry Of Health, Labour And Welfare (MHLW) For The Treatment Of Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

ULTOMIRIS® (ravulizumab) Receives Marketing Authorization From Japan's Ministry Of Health, Labour And Welfare (MHLW) For The Treatment Of Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved ULTOMIRIS ® (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks, for the...

Positive Phase 3 Extension Data For ULTOMIRIS® (ravulizumab) In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented At European Hematology Association (EHA) Congress

Positive Phase 3 Extension Data For ULTOMIRIS® (ravulizumab) In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented At European Hematology Association (EHA) Congress

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the presentation of new data demonstrating that ULTOMIRIS ® (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks, provided consistent efficacy and...

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Wedbush Securities Senior Vice President Of Equity Research Laura Chico, Ph.D. Initiates Coverage On Six Stocks In The Healthcare And BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA And SAGE

Wedbush Securities Senior Vice President Of Equity Research Laura Chico, Ph.D. Initiates Coverage On Six Stocks In The Healthcare And BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA And SAGE

LOS ANGELES, May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico, Ph.

Alexion To Present At The UBS Global Healthcare Conference

Alexion To Present At The UBS Global Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the UBS Global Healthcare Conference in New York, NY on Monday, May 20, 2019 at 11:30 a.

Alexion To Present At The RBC Capital Markets Annual Healthcare Conference

Alexion To Present At The RBC Capital Markets Annual Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the RBC Capital Markets Annual Healthcare Conference in New York, NY on Tuesday, May 21, 2019 at 9:30 a.

New England Journal Of Medicine Publishes Positive Phase 3 PREVENT Data For SOLIRIS® (eculizumab) In Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

New England Journal Of Medicine Publishes Positive Phase 3 PREVENT Data For SOLIRIS® (eculizumab) In Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the New England Journal of Medicine (NEJM) published positive data from the Phase 3 PREVENT study of SOLIRIS ® (eculizumab), a first-in-class complement inhibitor, in adult patients with...

Alexion Pharmaceuticals Takes Over #121 Spot From Electronic Arts

Alexion Pharmaceuticals Takes Over #121 Spot From Electronic Arts

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Alexion Pharmaceuticals Inc. has taken over the #121 spot from Electronic Arts, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGNC, ALXN, ATUS, BHF, CEQP, DLR, EDU, F, LKQ, MTX, WNC Downgrades: AKO.A, AKO.B, BABY, BC, BPRN, BRQS, EHTH, FNWB, IKNX, JNPR, KRA, MMLP, OMCL, TRN, UTHR, VIVO Initiations: BWB Read on to get TheStreet Quant Ratings' detailed report:

Alexion Receives Positive CHMP Opinion For ULTOMIRIS® (ravulizumab) In Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Receives Positive CHMP Opinion For ULTOMIRIS® (ravulizumab) In Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for ULTOMIRIS ®...

The New #37 Most Shorted Nasdaq 100 Component: Alexion Pharmaceuticals

The New #37 Most Shorted Nasdaq 100 Component: Alexion Pharmaceuticals

The most recent short interest data has been released for the 04/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Alexion Reports First Quarter 2019 Results

Alexion Reports First Quarter 2019 Results

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2019.

Alexion To Report First Quarter Results On Thursday, April 25, 2019

Alexion To Report First Quarter Results On Thursday, April 25, 2019

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2019 before the US financial markets open on April 25, 2019.

Alexion And Zealand Pharma Announce Collaboration To Discover And Develop Peptide Therapies For Complement-Mediated Diseases

Alexion And Zealand Pharma Announce Collaboration To Discover And Develop Peptide Therapies For Complement-Mediated Diseases

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Zealand Pharma A/S (NASDAQ:ZEAL) today announced a collaboration to discover and develop novel peptide therapies for complement-mediated diseases.

Alexion And Affibody Announce Partnership To Co-Develop Anti-FcRn Affibody® Molecule

Alexion And Affibody Announce Partnership To Co-Develop Anti-FcRn Affibody® Molecule

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Affibody AB today announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases.

Alexion Announces Publication Of Interim Data From Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy And Safety Of SOLIRIS® (Eculizumab) In Adult Patients With Generalized Myasthenia Gravis In Muscle & Nerve

Alexion Announces Publication Of Interim Data From Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy And Safety Of SOLIRIS® (Eculizumab) In Adult Patients With Generalized Myasthenia Gravis In Muscle & Nerve

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the publication of data from an interim analysis of the Phase 3 open-label extension study (ECU-MG-302) of REGAIN (ECU-MG-301) evaluating the long-term efficacy and safety of SOLIRIS®...

Alexion To Present At The Cowen 39th Annual Health Care Conference

Alexion To Present At The Cowen 39th Annual Health Care Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Cowen 39 th Annual Health Care Conference in Boston, MA on Tuesday, March 12, 2019 at 11:20 a.

Alexion Employees Raise Hands To Raise Awareness And #RallyforRare On Rare Disease Day

Alexion Employees Raise Hands To Raise Awareness And #RallyforRare On Rare Disease Day

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) is honored to support Rare Disease Day 2019 with the launch of #RallyforRare, a global social media campaign that aims to raise awareness of rare diseases.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

Alexion To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Alexion To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 8 th Annual SVB Leerink Global Healthcare Conference in New York, NY on Wednesday, February 27, 2019 at 11:00 a.

Alexion Pharma and Carnival Among Stocks Billionaire Ray Dalio Added in Q4

Alexion Pharma and Carnival Among Stocks Billionaire Ray Dalio Added in Q4

One of the world's largest hedge fund added these 'strong buy' stocks last quarter.

Alexion Announces Creation Of New Roles On Executive Leadership Team

Alexion Announces Creation Of New Roles On Executive Leadership Team

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced the creation of new roles within its executive leadership team.

Amazon, Your Game Plan, and More: Cramer's 'Mad Money' Recap (Friday 2/8/19)

Amazon, Your Game Plan, and More: Cramer's 'Mad Money' Recap (Friday 2/8/19)

Jim Cramer takes a closer look at Jeff Bezos, Amazon and your game plan for the end of earnings season.

Home Depot, U.S. Concrete, Marathon Petroleum: 'Mad Money' Lightning Round

Home Depot, U.S. Concrete, Marathon Petroleum: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Home Depot, U.S. Concrete, Marathon Petroleum, Constellation Brands, Alexion Pharmaceuticals and more.

Alexion Reports Fourth Quarter And Full Year 2018 Results

Alexion Reports Fourth Quarter And Full Year 2018 Results

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the fourth quarter and full year of 2018.

Alexion To Highlight Rare Disease Portfolio At Investor Day

Alexion To Highlight Rare Disease Portfolio At Investor Day

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that the Company will host an Investor Day on Wednesday, March 20, from 8:00am to 12:30pm ET.

Alexion And Caelum Biosciences Announce Collaboration To Develop Targeted Therapy For Light Chain (AL) Amyloidosis

Alexion And Caelum Biosciences Announce Collaboration To Develop Targeted Therapy For Light Chain (AL) Amyloidosis

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Caelum Biosciences today announced a collaboration to develop CAEL-101 for light chain (AL) amyloidosis.

TheStreet Quant Rating: B (Buy)